Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate binding protein pseudogenes are DNA sequences derived from GBP genes, which encode large GTPases induced by interferons and involved in immunity[2][4][8]. Pseudogenes, by definition, have lost protein-coding ability due to disabling mutations, truncations, or lack of regulation, and do not typically yield functional mRNA or protein[3][5]. While GBP proteins play important roles in immune signaling and pathogen defense, GBP pseudogenes are not known to have direct biological functions or disease involvement. In some cases, pseudogenes can regulate gene expression indirectly, such as by acting as RNA decoys for microRNAs, but there is no specific evidence or characterization of functional roles for the guanylate binding protein pseudogene ENSG00000233235[3][7]. As a pseudogene, it is not a valid therapeutic target for drug development or direct disease modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanylate binding protein pseudogene.